CURRENT BIOTECHNOLOGY

What better way to keep abreast of developments in this diverse field?

Current Biotechnology (formerly Current Biotechnology Abstracts) is a monthly current awareness publication which gives you comprehensive coverage of the literature of biotechnology products and processes with industrial and commercial application. It covers the production of

chemicals from biomass, biotechnology in energy production and waste treatment, new biotechnological techniques and new applications of classical biotechnology.

Each issue contains over 500 references with full abstracts drawn from over 500 journals, books, press releases, technical reports, and patents.



3754-92-6 Biopharmaceuticals and conventional drugs: clinical success rates.

In 1989, one third of new drugs clinically tested in the US were produced by biotechnology. The clinical development stage of biopharmaceuticals is compared to that of conventional drugs. Two groups of biopharmaceuticals are included: proteins derived from recombinant DNA technology and proteins derived from hybridomas. Conventional drugs are limited to new chemical entities not previously clinically tested. Success rates at clinical trials were 63–68% for recombinant DNA products, 35–48% for monoclonal antibodies and 32% for the selected group of conventional drugs.

Bienz-Tadmor, B.; Dicerbo, P. A.; Tadmor, G.; Lasagna, L. Center Study Drug Dev., Tufts Univ., Boston, MA, USA *Bio/Technology* May 1992, **10**(5), 521–525.

Annual Subscription Jan–Dec 1993

Current Biotechnology Volume 9 September 1891 Seaus 9 September 1891 (SSN 0860-8037 Aberracts 3878-4021 CODEN CUBIER

EC USA Rest of World **£395.00 \$790.00 £395.00**

Don't be without this invaluable publication – write to us for further details and receive a sample issue FREE!

Simply complete and return the slip below.



☐ Please send me a free sample issue of CB

Name
Position
Organisation
Address

Please return to:

Sales and Promotion Department, Royal Society of Chemistry Thomas Graham House, Science Park, Milton Road, Cambridge CB4 4WF, United Kingdom. To order please phone (0223) 420066 quoting your credit card details – we now accept Access/Visa/Mastercard/Eurocard Or write to the address below enclosing a cheque made payable to the Royal Society of Chemistry. We can also issue pro-forma invoices if required.




Reagent of the Year 1993

94205 calixarene C-Undecylcalix[4]resorcinarene monohydrate package sizes 1 g and 5 g

The Prize Winner 1993: Prof. Dr. Yasuhiro Aoyama Y. Aoyama, born 1945, studied at Kyoto University, Japan, under the direction of the late Prof. I. Tabushi and Prof. em. Z. Yoshida. After joining the groups of Prof. Y. Murakami (Kyushu Univ.; research associate),

Prof. H.Ogoshi (NUT, now Kyoto Univ.; associate professor), and Prof. T.G.Traylor (UC San Diego; associate research chemist), he became a full professor of chemistry at Nagaoka University of Technology (NUT) in 1988.



The	Read	ent:
1110	INCUG	CIII.

C-Undecylcalix[4]resorcinarene is a macrocyclic, bowl-shaped compound having unprecedented properties. It is a lipophilic host forming stable complexes with polar oxygen-functionalized guests. By complex formation water, glycerol, carbohydrates and other polyols as well as carboxylic acids and esters are solubilized in aprotic, organic solvents^[1]. The eight hydroxy groups which constitute the hydrophilic rim of the bowl-shaped compound form four independent sites for the hydrogen-bonding of guests^[3]. Polyols and dicarboxylic acids undergo very selective complexation depending

on the number of functional groups, their spatial arrangement and stereochemistry^[2,3]. Thus carbohydrates are very selectively complexed (ribose > fructose > glucose)^[4-6]. The bowl-shaped aromatic cavity leads to a considerable upfield shift of 'H-NMR signals of a complexed guest^[7] and to an induced circular dichroism with a chiral guest^[8]. This novel host can be used as an 'H-NMR-shift reagent and also as a reagent for determining the absolute configuration of a chiral guest (exciton chirality induction).

References:

Y. Aoyama, Y. Tanaka, H. Ogoshi,
 J. Am. Chem. Soc. 110, 634 (1988).
 Y. Tanaka, Y. Kato, Y. Aoyama,
 J. Am. Chem. Soc. 112, 2807 (1990).
 Y. Kikuchi, Y. Kato, Y. Tanaka,
 H. Toi, Y. Aoyama, J. Am. Chem. Soc. 113, 1349 (1991).
 Y. Aoyama, Y. Tanaka, H. Ogoshi,
 J. Am. Chem. Soc. 111, 5397 (1989).

[5] Y. Tanaka, Y. Ubukata, Y. Aoyama, Chem. Lett. 1905 (1989).
[6] Y. Tanaka, C. Khare, M. Yonezawa, Y. Aoyama, Tetrahedron Lett. 31, 6139 (1990).
[7] Y. Tanaka, Y. Aoyama, Bull. Chem.

Soc. J H. Ogoshi, [8] Y. 7 (1989). J. Am

Soc. Jpn. **63**, 3343 (1990). [8] Y. Kikuchi, K. Kobayashi, Y. Aoyama, J. Am. Chem. Soc. **114**, 1351 (1992).

Prize Committee 1993:

Prof. Dr. D. Enders, Aachen Prof. Dr. H.J. Hansen, Zürich Prof. Dr. G. Helmchen, Heidelberg Prof. Dr. G. Simchen, Stuttgart and Dr. W. Keller, Buchs.

The Fluka Prize:

Since 1987, the Fluka Prize "Reagent of the Year" has been awarded anually to a research project, in which a new compound has been shown to be a reagent of prime importance, useful in organic chemistry, biochemistry or analytical chemistry. The winner will be awarded the sum of sFr. 10'000.-. He will be free of any obligations whatsoever. Nominations for the Fluka Prize "Reagent of the Year" should be submitted to the Fluka Prize Committee c/o Fluka Chemie AG, CH-9470 Buchs/ Switzerland no later than September 30th. Full details regarding the Fluka Prize are available upon request.

Fluka



Fluka Chemie AG Industriestrasse 25 CH-9470 Buchs/Switzerland

